STOPAD consists of Carboxymethyl-chitosan and rTLH.
It is intended for use with internal hemostasis in surgical operations.
STOPAD makes the bleeding stop in 3 minutes.
As a result, it shrortens operation time and gives safety to patients.
STOPAD can be kept at the room temperature(1-30℃).
It is also biodegradable completely in vivo.
It induces the exudate absorption and coagulation of
blood platelet & red blood cell.
The created blood clot protects the wound as a mechanical barrier.
It cuts Fibrinogen’s α chain. (Fibrinogen to DesAA Fibrin)
DesAA Fibrin combines with platelets aggregation,
forming the blood clot. That is,
rTLH helps the activated thrombin at bleeding area, promoting hemostasis.
The clinical trial was completed in 104 patients at 3 major hospitals for
ensuring safety and effectiveness of STOPAD.
In more than 90% of cases, hemostasis was successful within 3 minutes,
demonstrating the excellent effect.
There was no serious adverse event such as allergic reactions and
all of vitals sign & lab test results were normal.
Patient with infection or contamination in the surgical area
Patient currently undergoing coagulant therapy
Patient with a severe case of anemia
Patient allergic to shellfish or Batroxobin
Patient with unstable hemodynamic state
Patient with a past or present history of Bleeding Disorders
for Bleeding Diseases